Presentation is loading. Please wait.

Presentation is loading. Please wait.

HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,

Published byJeffry Johns Modified over 9 years ago

Similar presentations

Presentation on theme: "HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,"— Presentation transcript:

1 HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse, P. Jacobs, J. Sorensen, A. J. Saxon, D. Metzger, W. Ling Perelman School of Medicine at Univ. of PA; Treatment Research Institute; Yale Univ.; Oregon Health & Sciences Univ.; Univ. of CA, Los Angeles; Univ. of CA, San Francisco; Veterans Affairs Puget Sound Health Care System, Seattle, WA JAIDS 2014; 66(3): 288-293

2 Protocol: NIDA-CTN-0027 Secondary Analyses of Data from “Starting Treatment with Agonist Replacement Therapies” (START) Protocol: NIDA-CTN-0027 Secondary Analyses of Data from “Starting Treatment with Agonist Replacement Therapies” (START) Drs. Walter Ling and Andrew Saxon, Lead Investigators University of Washington VA Puget Sound Health Care System Seattle, WA andrew.saxon@va.gov 206-764-2782 5 U10 DA013714-08 Donovan and Roll (PIs) NIDA Clinical Trials Network: Pacific Northwest Node

3 Disclosures Supported by National Institute on Drug Abuse Clinical Trials Network Supported by National Institute on Drug Abuse Clinical Trials Network Reckitt Benckiser provided Suboxone Reckitt Benckiser provided Suboxone

4 Objectives of Main Study The Food and Drug Administration (FDA) requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety. PRIMARY Compare changes in liver enzymes related to treatment with BUP/NX to changes in liver enzymes related to treatment with MET. SECONDARY Identify risk factors at baseline and during treatment that could contribute to interactions with BUP/NX or MET causing liver dysfunction. Assess abstinence from illicit substances. Assess abstinence from alcohol.

5 START Study Schema 1920Number screened for participation 1269Randomized 740Buprenorphine/Naloxone529Methadone 340Evaluable 400 Failed to remain on assigned medication for 24 wks 0Failed to provide ≥ 4 LT samples 391Evaluable 136Failed to remain on assigned medication for 24 wks 2Failed to provide ≥ 4 LT samples 261 Completed 32-week follow-up330 Completed 32-week follow-up

6 Outcome Measures/Analysis Primary Outcome Changes in liver enzymes (transaminases) Primary analysis Descriptive Shift Tables ≤2X ULN remain ≤2X ULN ≤2X ULN then ↑ >2X ULN >2X ULN then ↓ ≤2X ULN and remain ≤2X ULN >2X ULN do not ↓ ≤2X ULN or ↑ >2X eligibility value >2X then ↑ >2X eligibility value

7 Outcome Measures/Analysis About 10 secondary Outcomes Among them was HIV risk Measured by Risk Behavior Survey Self-reported injecting and sexual risk behaviors Window past 30 days Done at baseline and at weeks 12 and 24

8 Participant Characteristics BUP/NX (n=740)MET (n=529) Females238 (32.2%)170 (32.1%) Age37.5 (11.2)37.3 (10.9) Injected in past 30 days508 (68.6%)368 (69.6%)

9 Participant Characteristics BUP/NX (n=740)MET (n=529) Hispanic Ethnicity125 (16.9%)81 (15.3%) White514 (69.5%)392 (74.1%) African American63 (8.5%)47 (8.9%) Other Race163 (22%)90 (17%)

10 Baseline Substance Use % Reported Days Use Past 4 Weeks BUP/NX (n=740) M (SD) Median MET (n=529) M (SD) Median Opioids81.3 (32.1) 10082.5 (31.6) 100 Cocaine10.7 (23.5) 011.6 (23.3) 0 Alcohol4.6 (14.8) 05.8 (17.2) 0 Benzodiazepines2.1 (8.5) 01.8 (8.6) 0 Cannabis10.4 (26.5) 08.4 (22.8) 0

11 Baseline Substance Use % Positive Urine Drug Screen BUP/NX (n=740)MET (n=529) Opiates644 (87.0%)459 (86.8%) Oxycodone103 (13.9%)78 (14.7%) Cocaine252 (34.1%)222 (42.0%) Benzodiazepines141 (19.1%)95(18.0%) Cannabis187 (25.3%)113 (21.4%)

12 Dosing Highest Dose in mg MeanSDMedian BUP/NX (buprenorphine) 22.39.224 MET93.243.990  % dispensed ranged from 95.1% week 1 to 83.4% week 24  175.3 total dose years for BUP/NX  197.1 total dose years for MET

13 Treatment Retention

14 Opiate Positive UDS (%) GEE Analysis Bup*time χ 2 =92.41, p<.0001

15 Cocaine Positive UDS (%) GEE Analysis Bup*time χ 2 =40.55, p<.04

16 HIV Injection Risk Behavior Risk Behavior Survey completed at baseline, week 12, week 24 Risk Behavior Survey completed at baseline, week 12, week 24 Needle Sharing in Past 30 Days among Week 24 Completers: Baseline (%)Week 24 (%)p Bup/Nx (n=340)14.42.4<.0001 MET (n=391)14.14.8<.0001

17 HIV Sexual Risk Behavior Risk Behavior Survey completed at baseline, week 12, week 24 Risk Behavior Survey completed at baseline, week 12, week 24 Multiple Sexual Partners in Past 30 Days among Week 24 Completers: Baseline (%)Week 24 (%)p Bup/Nx (n=340)6.85.2<.04 MET (n=391)8.25.1<.04

18 Table 2: Injection drug use and needle risk behavior during the last 30 days VariableBUPMETP values a, b Baseline12 wk. FU24 wk. FUBaseline12 wk. FU24 wk. FUTx Time (Visit) Tx*time Mean number of times injected cocaine 1.81.10.772.21.51.2 0.881 3 0.18610.7585 Mean number of times injected heroin 64.61.92.765.33.94.4 0.669 5 <.00010.4797 Mean number of times injected speedball 2.30.690.224.10.740.42 0.537 5 <.00010.9633 Mean number of times injected other opiates 1.00.020.011.70.010.02 0.991 9 0.00080.7064 Mean number of times injected Amphetamines 0.050.071.90.290.020.22 0.049 7 0.61350.0363 Mean number of times injected Total 69.73.835.673.56.2 0.875 6 <.00010.9407 % Shared needles14.42.52.414.12.94.8 0.200 8 <.00010.1029 % Didn’t clean shared needles w/ bleach 10.31.8 9.91.63.2 0.369 2 <.00010.3009 % Shared cooker17.12.53.018.94.84.5 0.726 2 <.00010.2959 % Front/back load (any)21.23.14.620.55.94.5 0.704 9 <.00010.5311 % Needle risk composite 25.04.25.224.87.26.90.402 2 <.0001<.1923 a PROC GENMOD (Negative binomial distribution); b PROC GENMOD (GEE) for binary variables

19 Table 3: Sexual risk behavior during the last 30 days. VariableBUPMETP values c Baseline 12 wk. FU 24 wk. FU Baseline 12 wk. FU 24 wk. FU Tx Time (Visit) Tx*time % Multiple (>1) partners 6.87.95.28.24.35.10.67500.03290.3539 % Unsafe sex (without condom) 56.553.458.559.954.354.90.12170.05440.0534 % Sex risk composite 56.553.458.560.454.655.20.09420.04250.0451 c PROC GENMOD (GEE) for binary variables

20 Table 4a: Sexual risk behavior for male VariableMale BUPMETP values Baselin e (n=242 ) 12 week FU (n=234) 24 week FU (n=234) Baselin e (n=253) 12 week FU (n=243) 24 week FU (n=245) Tx Time (visit) Tx*tim e % Multiple (>1) partners5.798.125.135.533.293.270.97280.13700.2931 % Unsafe sex (without condom) 39.2639.3244.0242.2940.7441.220.24720.83700.1279 % Sex risk composite41.3245.3047.4446.2542.3944.080.15750.55540.0318

21 Table 4b: Sexual risk behavior for female VariableFemale BUPMETP values Baselin e (n=98) 12 week FU (n=92) 24 week FU (n=96) Baseline (n=138) 12 week FU (n=131) 24 week FU (n=130) Tx Time (visit) Tx*tim e % Multiple (>1) partners9.187.615.2113.046.118.460.69890.12920.9470 % Unsafe sex (without condom) 44.9042.3940.6348.5541.2241.540.57500.10550.5598 % Sex risk composite52.0446.7444.7955.8045.8045.380.54890.02450.5433

22 Summary BIG and equal reduction in opioid injecting risk in both groups for patients who remained in their assigned condition Increase in #times amphetamines injected in bup pts. But, overall level of amphetamine use very low Sex risk low in both groups Sex risk low in both groups

23 Summary (continued) Sex risk significantly lower in male methadone patients, but h igher in male bup patients Sex risk significantly lower in male methadone patients, but h igher in male bup patients Consistent with differences in gonadal suppressing effects of methadone vs bup Consistent with differences in gonadal suppressing effects of methadone vs bup For females, sex risk risk significantly lower in both methadone and bup patients For females, sex risk risk significantly lower in both methadone and bup patients Consistent with reduction in drug use & leading to less exchanging sex for drugs in females Consistent with reduction in drug use & leading to less exchanging sex for drugs in females

24 Summary (continued) If consider differential dropout, conclusion is that methadone resulted in better HIV risk reduction If consider differential dropout, conclusion is that methadone resulted in better HIV risk reduction Because more methadone pts. stayed in rx Because more methadone pts. stayed in rx If consider only those that stayed in treatment, methadone and bup both produced equal and marked reduction in injecting risk If consider only those that stayed in treatment, methadone and bup both produced equal and marked reduction in injecting risk Recommendations for patients? Recommendations for patients?

25 Thanks to the CTN Network that did the trial! Thanks to the CTN Network that did the trial! Evergreen Treatment Services, and the Pacific Northwest Node CODA Inc. and the Oregon Hawaii Node Bi-Valley Medical Clinic, and the California/Arizona Node Connecticut Counseling Centers Hartford Dispensary, and the New England Node NET Steps, and the Delaware Valley Node Bay Area Addiction Research & Treatment Matrix Institute, and the Pacific Region Node Addiction Research & Treatment Corp, and the New York Node Medical University of South Carolina - Genetics University of Pennsylvania – Genetics Rutgers Cell and DNA Repository UCLA - Retention Duke Clinical Research Institute (DSC) EMMES Corporation (CCC) & our CCTN liaisons‘ and NIDA Sponsor!

Download ppt "HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,"

Similar presentations

The effect of gender specific HIV prevention interventions on heterosexual anal sex among men and women in substance abuse treatment Donald A. Calsyn,

The effect of gender specific HIV prevention interventions on heterosexual anal sex among men and women in substance abuse treatment Donald A. Calsyn,
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.

Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Influences of Marijuana Use on Adolescent HIV/STI Acquisition and Care Jonathan M. Ellen, MD Johns Hopkins School of Medicine.

Influences of Marijuana Use on Adolescent HIV/STI Acquisition and Care Jonathan M. Ellen, MD Johns Hopkins School of Medicine.
Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.

Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.

Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Behavioral Intention and Partner Type on Condom Use Among Men in Drug Treatment Yong S. Song, PhD, University of California, San Francisco Donald Calsyn,

Behavioral Intention and Partner Type on Condom Use Among Men in Drug Treatment Yong S. Song, PhD, University of California, San Francisco Donald Calsyn,
C. Andres Bedoya, PhD Behavioral Medicine Service Department of Psychiatry Massachusetts General Hospital / Harvard Medical School Factors related to high-risk.

C. Andres Bedoya, PhD Behavioral Medicine Service Department of Psychiatry Massachusetts General Hospital / Harvard Medical School Factors related to high-risk.
Hepatitis C Awareness and Risky Injection Behaviors among Injection Drug Users in Treatment PT Korthuis 1, D Feaster 2, Z Gomez 2, M Das-Douglas 3, S Tross.

Hepatitis C Awareness and Risky Injection Behaviors among Injection Drug Users in Treatment PT Korthuis 1, D Feaster 2, Z Gomez 2, M Das-Douglas 3, S Tross.
Killing the Pain: Prescription Drug Abuse and Other Risky Behaviors in Rural Appalachia Jennifer R. Havens, PhD, MPH Department of Behavioral Science Center.

Killing the Pain: Prescription Drug Abuse and Other Risky Behaviors in Rural Appalachia Jennifer R. Havens, PhD, MPH Department of Behavioral Science Center.
HIV INTERVENTION FOR PROVIDERS (HIP) Principal Investigators:  Carol Dawson Rose, RN, Ph.D. and Grant Colfax, MD. Co-Investigators:  Cynthia Gomez, Ph.D.,

HIV INTERVENTION FOR PROVIDERS (HIP) Principal Investigators:  Carol Dawson Rose, RN, Ph.D. and Grant Colfax, MD. Co-Investigators:  Cynthia Gomez, Ph.D.,
Long-Term Course of Opioid Addiction Long-Term Course of Opioid Addiction Yih-Ing Hser, Ph.D. UCLA Integrated Substance Abuse Programs Addiction Seminar.

Long-Term Course of Opioid Addiction Long-Term Course of Opioid Addiction Yih-Ing Hser, Ph.D. UCLA Integrated Substance Abuse Programs Addiction Seminar.
Www.aodhealth.org1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Race/Ethnicity as a Moderator of HIV/STD Sexual Risk Reduction Groups for Women in Substance Abuse Treatment E. Bell 1, S. Tross 2, A.N.C. Campbell 1,3,

Race/Ethnicity as a Moderator of HIV/STD Sexual Risk Reduction Groups for Women in Substance Abuse Treatment E. Bell 1, S. Tross 2, A.N.C. Campbell 1,3,
Audrey J. Brooks, PhD University of Arizona CA-AZ node.

Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.

Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.

Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA013045 Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.

NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.

The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.

Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.

Similar presentations

Ads by Google